EMA considers new biomarkers, patient populations in proposed Parkinson’s disease guideline update
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesClinical TrialsEuropeEuropean Medicines Agency (EMA)GuidancePharmaceuticalsProduct development